Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Total Liabilities (2022 - 2025)

Core Laboratories (CLB) has 4 years of Total Liabilities data on record, last reported at $320.0 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 6.99% year-over-year to $320.0 million; the TTM value through Sep 2025 reached $320.0 million, down 6.99%, while the annual FY2024 figure was $338.4 million, 5.1% down from the prior year.
  • Total Liabilities reached $320.0 million in Q3 2025 per CLB's latest filing, down from $334.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $403.8 million in Q2 2022 and bottomed at $320.0 million in Q3 2025.
  • Average Total Liabilities over 4 years is $361.2 million, with a median of $358.5 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: fell 8.43% in 2023, then fell 4.91% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $389.4 million in 2022, then decreased by 8.43% to $356.6 million in 2023, then decreased by 5.1% to $338.4 million in 2024, then fell by 5.44% to $320.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $320.0 million in Q3 2025, $334.8 million in Q2 2025, and $332.2 million in Q1 2025.